McDermott Will & Schulte advises founders, startups, as well as venture capital, private equity and debt funds throughout the company lifecycle. The team provides strategic guidance on startup formation, due diligence and multi-stage funding rounds, from Series A through Series C. The practice is led by Fabrice Piollet, Diana Hund, Anthony Paronneau and Emmanuelle Trombe.
Legal 500 Editorial commentary
Key clients
- Nov Santé Actions Non Cotées (Eurazeo)
- Riot
- Crédit Mutuel Innovation
- Owkin
- Brightflow SAS
- Brenus Pharma
- Abolis Biotechnologies
- Spotlight Medical
- Cilcare
- Orakl Oncology
- Soffinova Partners
Work highlights
Advising the Nov Santé Actions Non Cotées fund on its third growth equity investment in Germitec, a French MedTech innovator in high-level disinfection of ultrasound probes.
Advising Crédit Mutuel Innovation, the VC arm of Crédit Mutuel Equity and Crédit Mutuel Alliance Fédérale group, on the €44m Series C financing of UroMems, an international medtech company developing an innovative, implantable mechatronic technology to treat stress urinary incontinence.
Advising Owkin, a leading AI-driven biotechnology unicorn, on the €41m Series A fundraising of Bioptimus, the first universal AI model designed to fuel breakthrough discoveries and accelerate innovation in biomedicine.
Practice head
Fabrice Piollet; Diana Hund; Anthony Paronneau; Emmanuelle Trombe